The FDA has approved upadacitinib, a Janus kinase inhibitor, for the treatment of giant cell arteritis in adults-marking the ...

Patients in the US with newly diagnosed GCA face excessive delays to initiating subcutaneous TCZ, as well high out-of-pocket costs.

The FDA has approved Rinvoq (upadacitinib), a Janus kinase inhibitor, for the treatment of adults with giant cell arteritis.

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...